loading page

Report of clinical presentations and two novel mutations in patients with Wiskott-Aldrich Syndrome/X-linked thrombocytopenia
  • +4
  • Natsumon Udomkittivorakul,
  • Pongpak Pongphitcha,
  • Duangrurdee Wattanasirichaigoon,
  • Wiparat Manuyakorn,
  • Arthaporn Khongkraparn,
  • Padcha Tunlayadechanont,
  • Nongnuch Sirachainan
Natsumon Udomkittivorakul
Mahidol University Faculty of Medicine Ramathibodi Hospital
Author Profile
Pongpak Pongphitcha
Mahidol University Faculty of Medicine Ramathibodi Hospital
Author Profile
Duangrurdee Wattanasirichaigoon
Mahidol University Faculty of Medicine Ramathibodi Hospital
Author Profile
Wiparat Manuyakorn
Mahidol University Faculty of Medicine Ramathibodi Hospital
Author Profile
Arthaporn Khongkraparn
Mahidol University Faculty of Medicine Ramathibodi Hospital
Author Profile
Padcha Tunlayadechanont
Mahidol University Faculty of Medicine Ramathibodi Hospital
Author Profile
Nongnuch Sirachainan
Mahidol University Faculty of Medicine Ramathibodi Hospital

Corresponding Author:[email protected]

Author Profile

Abstract

Wiskott-Aldrich syndrome (WAS)/X-linked thrombocytopenia (XLT) is a rare X-linked disease characterized by thrombocytopenia, eczema, and recurrent infection. In addition, WAS/XLT increases incidence of autoimmune diseases and malignancies. We reported 7 male patients, 2 with WAS and 5 with XLT, from 6 different families. Two novel mutations, p.Gly387GlufsTer58 and p.Ala134Asp, were identified in patients with WAS. Both patients had severe clinical phenotypes compatible with classic WAS and developed lethal outcomes with intracranial hemorrhage. Other than that, one patient with XLT developed pineoblastoma.